Yes, Theracour is the stock to own, which is why Dr. Diwan keeps it to himself and a handful of insiders.
Case 1: Nanoviricides fails utterly. Theracour, which makes 30% over expenses every year, walks away with a respectable profit. Most of the money shareholders invested in NNVC's winds up lying in the bank accounts of Theracour and its officers.
Case 2: Nanoviricides gets some 'cides approved. Theracour continues to make 30% on all development, plus gets royalties on the 'cides.
Case 3. Nanoviricdes gets some 'cides approved, and Big Pharma starts bidding -- for Theracour, which owns all the intellectual property. Theracour cashes out big time. Nanoviricides shareholders lose, because for each new 'cide they must negotiate with a corporate entity whose sole goal is to keep as much of the revenues for itself as possible. Big Pharma, with Theracour's IP, will have no fiduciary obligation to maximize NNVC's profits.
It is not possible for Theracour to lose. Can you say that about NNVC?
News 
Market Data 
Discover 
